Company: SRPT
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001193125-25-044088
Chunk: 5

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 5
---
 and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare
diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne and are developing potential
therapeutic candidates for a broad range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies, and other neuromuscular disorders, such as facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1, and central
nervous system related disorders.

We commercialize four products, all of which were granted accelerated approval or traditional approval
by the FDA: EXONDYS 51 (eteplirsen) Injection, indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping, VYONDYS 53 (golodirsen) Injection, indicated for the
treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping, AMONDYS 45 (casimersen) Injection, indicated for the treatment of Duchenne in patients who have a confirmed mutation of the
dystrophin gene that is amenable to exon 45 skipping, and ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus-based gene therapy for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed
mutation in the Duchenne gene. ELEVIDYS is also approved for non-ambulatory patients under the accelerated approval pathway.

Our pipeline includes programs in various stages of pre-clinical and clinical development, reflecting
our multifaceted approach and expertise in genetic medicines aimed at making a profound difference in the lives of patients suffering from rare diseases.

Corporate Information

We were originally
incorporated in the State of Oregon on July 22, 1980, and on June 6, 2013, we reincorporated in the State of Delaware. Our principal executive offices are located at 215 First Street, Suite 415, Cambridge, MA 02142 and our telephone number
is (617) 274-4000. On July 12, 2012, our common stock began trading under the symbol “SRPT” on the Nasdaq Global Market. Our common stock